Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2016 - 2018)

Neurocrine Biosciences (NBIX) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $18.1 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 477.8% year-over-year to $18.1 million, compared with a TTM value of $18.1 million through Dec 2018, up 477.8%, and an annual FY2018 reading of $18.1 million, up 477.8% over the prior year.
  • Non-Current Deffered Revenue was $18.1 million for Q4 2018 at Neurocrine Biosciences, up from $12.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $18.1 million in Q4 2018 and bottomed at $1.3 million in Q1 2017.
  • Average Non-Current Deffered Revenue over 5 years is $5.8 million, with a median of $3.1 million recorded in 2017.
  • The sharpest move saw Non-Current Deffered Revenue crashed 84.46% in 2016, then surged 500.41% in 2017.
  • Year by year, Non-Current Deffered Revenue stood at $1.9 million in 2014, then soared by 445.07% to $10.2 million in 2015, then changed by 0.0% to $10.2 million in 2016, then crashed by 69.36% to $3.1 million in 2017, then skyrocketed by 477.8% to $18.1 million in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for NBIX at $18.1 million in Q4 2018, $12.1 million in Q3 2018, and $10.2 million in Q2 2018.